Contribution of Noncanonical Splice Variants to TTN Truncating Variant Cardiomyopathy

Supplemental Digital Content is available in the text. Background: Heterozygous TTN truncating variants cause 10% to 20% of idiopathic dilated cardiomyopathy (DCM). Although variants which disrupt canonical splice signals (ie, invariant dinucleotide of the splice donor site, invariant dinucleotide of the splice acceptor site) at exon-intron junctions are readily recognized as TTN truncating variants, the effects of other nearby sequence variations on splicing and their contribution to disease is uncertain. Methods: Rare variants of unknown significance located in the splice regions of highly expressed TTN exons from 203 DCM cases, 3329 normal subjects, and clinical variant databases were identified. The effects of these variants on splicing were assessed using an in vitro splice assay. Results: Splice-altering variants of unknown significance were enriched in DCM cases over controls and present in 2% of DCM patients (P=0.002). Application of this method to clinical variant databases demonstrated 20% of similar variants of unknown significance in TTN splice regions affect splicing. Noncanonical splice-altering variants were most frequently located at position +5 of the donor site (P=4.4×107) and position -3 of the acceptor site (P=0.002). SpliceAI, an emerging in silico prediction tool, had a high positive predictive value (86%–95%) but poor sensitivity (15%–50%) for the detection of splice-altering variants. Alternate exons spliced out of most TTN transcripts frequently lacked the consensus base at +5 donor and −3 acceptor positions. Conclusions: Noncanonical splice-altering variants in TTN explain 1-2% of DCM and offer a 10-20% increase in the diagnostic power of TTN sequencing in this disease. These data suggest rules that may improve efforts to detect splice-altering variants in other genes and may explain the low percent splicing observed for many alternate TTN exons.

[1]  William J. Astle,et al.  The Polygenic and Monogenic Basis of Blood Traits and Diseases , 2020, Cell.

[2]  Angharad M Roberts,et al.  Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy , 2020, Circulation.

[3]  D. Baralle,et al.  Machine Learning Approaches for the Prioritization of Genomic Variants Impacting Pre-mRNA Splicing , 2019, Cells.

[4]  N. Pereira,et al.  Genetics of dilated cardiomyopathy: practical implications for heart failure management , 2019, Nature Reviews Cardiology.

[5]  Raquel Yotti,et al.  Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies. , 2019, Annual review of genomics and human genetics.

[6]  David G. Knowles,et al.  Predicting Splicing from Primary Sequence with Deep Learning , 2019, Cell.

[7]  Jacob T. Munro,et al.  A gene-centric strategy for identifying disease-causing rare variants in dilated cardiomyopathy , 2018, Genetics in Medicine.

[8]  Parth N. Patel,et al.  In Vivo and In Vitro Methods to Identify DNA Sequence Variants that Alter RNA Splicing , 2018, Current protocols in human genetics.

[9]  Amanda C. Garfinkel,et al.  Genetic Pathogenesis of Hypertrophic and Dilated Cardiomyopathy. , 2018, Heart failure clinics.

[10]  Parth N. Patel,et al.  Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing , 2017, Proceedings of the National Academy of Sciences.

[11]  Kamil J. Cygan,et al.  Pathogenic variants that alter protein code often disrupt splicing , 2017, Nature Genetics.

[12]  R. Płoski,et al.  Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations , 2017, PloS one.

[13]  Daniel Rueckert,et al.  Titin truncating variants affect heart function in disease cohorts and the general population , 2016, Nature Genetics.

[14]  D. MacArthur,et al.  Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.

[15]  Stuart A. Cook,et al.  Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy. , 2016, Journal of the American College of Cardiology.

[16]  Matthias Heinig,et al.  Alternative Splicing Signatures in RNA‐seq Data: Percent Spliced in (PSI) , 2015, Current protocols in human genetics.

[17]  Ellen T. Gelfand,et al.  A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project , 2015, Biopreservation and biobanking.

[18]  George Church,et al.  Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy , 2015, Science.

[19]  Tan Ru San,et al.  Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease , 2015, Science Translational Medicine.

[20]  N. Rajewsky,et al.  RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. , 2014, The Journal of clinical investigation.

[21]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[22]  D. Hedges,et al.  Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.

[23]  Helen M. Moore.  Acquisition of normal tissues for the GTEx program. , 2013, Biopreservation and biobanking.

[24]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[25]  P. Ellinor,et al.  RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing , 2012, Nature Medicine.

[26]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[27]  L. Mestroni,et al.  Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.

[28]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[29]  N. Norton,et al.  Identification of Novel Mutations in RBM20 in Patients with Dilated Cardiomyopathy , 2010, Clinical and translational science.

[30]  E. McNally,et al.  The genetics of dilated cardiomyopathy , 2010, Current opinion in cardiology.

[31]  T. Frebourg,et al.  Use of splicing reporter minigene assay to evaluate the effect on splicing of unclassified genetic variants. , 2010, Methods in molecular biology.

[32]  H. Watkins,et al.  Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency* , 2009, Circulation research.

[33]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[34]  F. T. ten Cate,et al.  Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction , 2009, Circulation.

[35]  Peter Devilee,et al.  Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice‐site prediction programs , 2009, Human mutation.

[36]  Ferhaan Ahmad,et al.  Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. , 2008, Journal of molecular and cellular cardiology.

[37]  J. Hampe,et al.  Single base‐pair substitutions in exon–intron junctions of human genes: nature, distribution, and consequences for mRNA splicing , 2007, Human mutation.

[38]  Christopher B. Burge,et al.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals , 2003, RECOMB '03.

[39]  Marvin B. Shapiro,et al.  RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. , 1987, Nucleic acids research.